SCHEMBL5338078

SCHEMBL5338078

CCCCOC(=O)C1=C(C)NC2=C(C(=O)CC(c3ccccc3)C2)C1c1ccco1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.56
HSD17B10 Q99714 6/20 0.56
GAA P10253 4/20 0.56
TSHR P16473 3/20 0.56
GLA P06280 2/20 0.56
ALDH1A1 P00352 9/20 0.51
HPGD P15428 4/20 0.51
NPSR1 Q6W5P4 2/20 0.51
HTT P42858 1/20 0.51
POLB P06746 5/20 0.51
LMNA P02545 3/20 0.51
AGTR1 P30556 1/20 0.51
CASP1 P29466 4/20 0.51
CASP7 P55210 4/20 0.51
USP2 O75604 2/20 0.51
TP53 P04637 2/20 0.51
ALOX15 P16050 1/20 0.51
RAB9A P51151 2/20 0.50
MAPK1 P28482 1/20 0.50
ADORA2B P29275 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5476494 0.84 FFAR3 (0.54) KDM4EHSD17B10GAATSHRGLA
SCHEMBL3323801 0.83 ALDH1A1 (0.57) KDM4EHSD17B10GAATSHRGLA
SCHEMBL3325469 0.82 KDM4E (0.50) KDM4EHSD17B10GAATSHRGLA
SCHEMBL3325585 0.80 KDM4E (0.53) KDM4EHSD17B10GAATSHRGLA
SCHEMBL12932132 0.80 KDM4E (0.57) KDM4EHSD17B10GAATSHRGLA
SCHEMBL5317053 0.79 ALDH1A1 (0.75) KDM4EHSD17B10GAATSHRALDH1A1
SCHEMBL3324425 0.79 ALDH1A1 (0.55) KDM4EHSD17B10GAAGLAALDH1A1
SCHEMBL3324836 0.79 ALDH1A1 (0.61) KDM4EHSD17B10GAATSHRGLA
SCHEMBL5332348 0.78 KDM4E (0.51) KDM4EHSD17B10GAAGLAALDH1A1
SCHEMBL3329937 0.78 ALDH1A1 (0.51) KDM4EHSD17B10GAATSHRGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120245147-A1 INHIBITORS OF THAPSIGARGIN-INDUCED CELL DEATH NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2012-09-27 US claimed
US-20070112015-A1 Substituted dihydropyridines and methods of use CHEMOCENTRYX, INC. (US) 2007-05-17 US disclosed
WO-2007051062-A2 SUBSTITUTED DIHYDROPYRIDINES AND METHODS OF USE CHEMOCENTRYX, INC. (US) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120245147-A1 INHIBITORS OF THAPSIGARGIN-INDUCED CELL DEATH HSPA5, HSP90B1, ATP2A1 KDM4E 3850/4885HSD17B10 2678/4885GAA 239/4885
US-20070112015-A1 Substituted dihydropyridines and methods of use C3AR1, C5AR1, C5AR2 KDM4E 4033/4885HSD17B10 3999/4885GAA 3421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.